FindTrial
Sign In

Safety of low dose Ramipril in voluntary kidney donors after donation.

Safety of low dose ACE inhibition in living kidney donors.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039109
Enrollment
75
Registered
2022-01-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Ramipril 1.25mg: Low dose ACE inhibitor Ramipril 1.25mg will be given to live kidney donors post donation for 6 months. Control Intervention1: NIL: Nil

Sponsors

Department of Nephrology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) age 18 to 60 years

Exclusion criteria

Exclusion criteria: 1) diagnosis of hypertension 2) history of allergy to ACE inhibitors 3) History of angioedema 4) history of allergy to iodinated contrast media 5) systolic BP 6)Planning pregnancy in next 9 months after renal donation (females)

Design outcomes

Primary

MeasureTime frame
To evaluate safety of low dose ACEi (Ramipril 1.25mg) in living kidney donors.Timepoint: 6 months—

Secondary

MeasureTime frame
To ascertain change in measured GFR in living donors at 6 months after kidney donation by plasma clearance of IohexolTimepoint: 6 months;To ascertain change in vascular stiffness in living donors at 6 months after kidney donation by PWVTimepoint: 6 months—

Countries

India

Contacts

Public ContactDr Ankur Chaudhary

PGIMER, Chandigarh

enigma165@gmail.com7087429731

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026